GRI Bio Seeks 546,529-Share Equity Plan Expansion, Lifting Overhang to 21%
GRI sits 52% above its 52-week low of $1.36 on light trading volume (0.4× avg).
Summary
GRI Bio's definitive proxy seeks approval to expand its equity incentive plan by 546,529 shares, raising potential dilution to 21% of outstanding shares, and to extend the evergreen provision to 2036.
Key Events · Corporate Governance and Compliance · GRI
-
Equity Plan Expansion Proposed
Proposal 3 seeks to increase shares authorized under the A&R 2018 Plan by 546,529, from 34,951 to 581,480 shares, raising equity overhang from 1.57% to 21.01%.
-
Evergreen Provision Extended to 2036
The amendment extends the evergreen provision to January 1, 2036, adding annual increases of 4% of outstanding shares each year through 2036.
-
Annual Meeting Scheduled
The 2026 Annual Meeting will be held virtually on November 4, 2026, with a record date of September 22, 2026 and 2,186,115 shares eligible to vote.
-
Auditor Ratification
Proposal 2 seeks ratification of WithumSmith+Brown, PC as independent auditor for fiscal 2026, following the April 2025 dismissal of Sadler, Gibb & Associates.
Analysis · GRI · Life Sciences
The proxy asks shareholders to approve a 546,529-share increase to the 2018 Equity Incentive Plan, which would raise the equity overhang from 1.57% to 21.01% of outstanding shares. For a micro-cap company with a going-concern warning and a market value below Nasdaq's proposed $5 million MVLS threshold, this expansion is a material governance and dilution event. The plan also extends the evergreen provision to 2036, allowing automatic annual increases of 4% of outstanding shares. The annual meeting is set for November 4, 2026.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRI was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.36 to $64.12. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.